References
- Mann NJ, Li D, Sinclair AJ et at. The effect of diet on plasma homocysteine concentrations in healthy male subjects. Euij Gun. Nun: 53(11), 895–899 (1999).
- Eikelboom JVV, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med 131(5), 363–375 (1999).
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl. I Med 338(15), 1042–1050 (1998).
- The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288(16), 2015–2022 (2002). Thorough meta-analysis that describes and sumrnerizes the clinical studies.
- Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JÁN/A 288(16), 2023-2031 (2002).
- Selhub J, Jacques PF, Rosenberg TH et al Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991–1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann. Intern. Med. 131(5), 331–339 (1999).
- Bostom AG, Culleton BE Hyperhomocysteinemia in chronic renal disease. Am. Soc. Nephrol. 10 (4), 891–900 (1999).
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 354(9176), 407–413 (1999).
- Frosst P, Blom HJ, Milos R et al A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nature Genet. 10(1),111–113 (1995).
- Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl. Med 340(19), 1449–1454 (1999).
- Kuzminski AM, Del Giacco EJ, Allen RII, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. B/ooc/92(4), 1191–1198 (1998).
- The Homocysteine Studies Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Brit. Med. 316(7135), 894–898 (1998).
- Schnyder G, Roffi M, Pin R etal. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Eng. Med. 345(22), 1593–1600 (2001).
- Vermeulen EG, Stehouwer CD, Twisk JW et al Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 355(9203), 517–522 (2000).
- van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol. 21 (12), 2072–2079 (2001).
- Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl. J. Med. 332(5), 328–329 (1995).
- Homberger J, Wrone E. When to base clinical policies on observational versus randomized trial data. Ann. Intern. Med. 127(8 Pt 2), 697–703 (1997).
- Homberger J. A cost-benefit analysis of a cardiovascular disease prevention trial, using folate supplementation as an example. Am.j Pub. Health 88(1), 61–67 (1998).
- Tice JA, Ross E, Coxson PG eta]. Cost- effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAIVIA 286(8), 936–943 (2001).
- •Describes a relevant cost-effectiveness analysis.
- Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar RR, Omenn GS. Potential clinical and economic effects of homocyst(e)ine lowering. Arch. Intern. Med. 160(22), 3406–3412 (2000).
- •Describes a relevant cost-effectiveness analysis.
- Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int. 52(1), 10–20 (1997).
- Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end stage renal disease. Am. J. Kidney Dis. 38(4 Suppl. 1), S91—S94 (2001).
- Wrone EM, Zehnder JL, Homberger JM, McCann LM, Coplon NS, Fortmann SR An MTHFR variant, homocysteine and cardiovascular comorbidity in renal disease. Kidney Int. 60(3), 1106–1113 (2001).
- de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99(6), 779–785 (1999).
- Vollmer WM, Sacks FM, Airl J etal Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann. Intern Med. 135(12),1019–1028 (2001).
- Sacks FM, Svetkey LP, Vollmer WM et al Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Eng. Merl 344(1), 3–10 (2001).
- Rosenson RS, Kang DS. Hyperhomocystinemia, Atherosclerosis and Venous Tbromboembolism. Rose B (Ed). Wellesley, MA, USA (2002).
Websites
- www.clinicaltrials.gov/ct/gui/show NCT00032435?order = 2.